Letrozole

IUPAC name

4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile

CAS No.

112809-51-5

Molecular Weight

285.30 g·mol−1

Molecular Formula

C17H11N5

Mechanism Of Action:

Letrozole works by blocking the enzyme aromatase, which turns the hormone androgen into small amounts of estrogen in the body, leads to less available estrogen to stimulate the growth or hormone receptor-positive breast cancer cells.

Indication:

  • Adjuvant Treatment of Early Breast Cancer; for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
  • Extended Adjuvant Treatment of Early Breast Cancer; for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.

 

  • First And Second-Line Treatment of Advanced Breast Cancer; for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. It is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.